Management of Silver–Russell Syndrome
April 25, 2022
No Comments
A 4-year-old girl is referred to the local paediatric endocrine unit with signs of pubertal development.
Topic: Growth disorders
Switch from daily to weekly rhGH feasible and popular for children with GHD
April 4, 2022
No Comments
Children with growth hormone deficiency maintain their growth trajectories if they switch from a daily recombinant human growth hormone to weekly lonapegsomatropin, and the vast majority prefer the less frequent injections, show the results of the fliGHt trial.
Silver-Russell syndrome patients derive lasting height and BMI benefits from rhGH treatment
April 4, 2022
No Comments
Treatment with recombinant human growth hormone results in an increased final adult height in children with molecularly confirmed Silver–Russell syndrome, as well as an improved BMI that persists after treatment cessation, say researchers.
Growth hormone benefit in Noonan syndrome demonstrated regardless of PTPN11 mutation status
April 4, 2022
No Comments
The benefit of initiating recombinant human growth hormone before puberty in patients with Noonan syndrome occurs regardless of whether the children carry a PTPN11 mutation, suggests research published in Endocrine Connections.
Inflammatory biomarkers elevated in paediatric Cushing’s syndrome
February 28, 2022
No Comments
Blood-cell markers of inflammation are elevated in children with Cushing’s syndrome and may offer useful diagnostic information, say researchers.
Weekly somapacitan efficacy matches daily rhGH over 3 years in GHD
January 31, 2022
No Comments
The 3-year findings of the REAL 3 trial show that weekly somapacitan continued to deliver equivalent height gains and safety results to that achieved with standard daily recombinant human growth hormone treatment in children with growth hormone deficiency.
Encouraging real-world CV safety profile for rhGH in Noonan syndrome
January 31, 2022
No Comments
Treatment with recombinant human growth hormone is not associated with cardiovascular adverse events in clinical practice, show data from two large, multicentre cohorts.
Promising height velocity with rhGH therapy in aggrecan-deficient children
January 31, 2022
No Comments
Young children with short stature due to aggrecan deficiency achieve a marked improvement in height velocity during their first year of treatment with recombinant human growth hormone, shows a cohort study.
Additional clinical features point to likely monogenic cause of short stature
December 21, 2021
No Comments
The likelihood of finding an underlying genetic cause of short stature in children is markedly increased if they have additional factors such as dysmorphic facial features or skeletal dysplasia, say researchers.
Identification of GH insensitivity among short children with normal GH secretion
November 1, 2021
No Comments
The evaluation of children presenting with short stature includes detailed clinical, phenotypic, auxological and biochemical assessments with genetic analyses in selected cases.
